1. Home
  2. NBIX
  3. NBIX News

Latest Neurocrine Biosciences Inc. (NBIX) News on May 10, 2025

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
NBIX

Simply Wall St.

2 days ago

Neurocrine Biosciences, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
NBIX

PR Newswire

2 days ago

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

NBIX

MT Newswires

3 days ago

Neurocrine Biosciences Insider Sold Shares Worth $3,305,952, According to a Recent SEC Filing

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
NBIX

Simply Wall St.

3 days ago

Neurocrine Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday
NBIX

Insider Monkey

4 days ago

Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday

NBIX

Argus Research

4 days ago

NBIX: Raising target price to $125.00

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
NBIX

Investor's Business Daily

4 days ago

Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May
NBIX

PR Newswire

4 days ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in May

NBIX

MT Newswires

4 days ago

BofA Securities Adjusts Price Target on Neurocrine Biosciences to $183 From $179, Maintains Buy Rating

NBIX

MT Newswires

4 days ago

UBS Adjusts Price Target on Neurocrine Biosciences to $152 From $137, Buy Rating Kept

NBIX

Thomson Reuters StreetEvents

4 days ago

Q1 2025 Neurocrine Biosciences Inc Earnings Call

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia
NBIX

PR Newswire

4 days ago

Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie™ Awareness Campaign for People with Tardive Dyskinesia

NBIX

MT Newswires

4 days ago

RBC Raises Price Target on Neurocrine Biosciences to $145 From $137, Keeps Outperform Rating

NBIX

GuruFocus.com

5 days ago

Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ...

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
NBIX

Zacks

5 days ago

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
NBIX

Zacks

5 days ago

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

NBIX

MT Newswires

5 days ago

Neurocrine Biosciences Q1 Non-GAAP Earnings Fall, Sales Rise; Maintains 2025 Guidance

NBIX

Associated Press Finance

5 days ago

Neurocrine: Q1 Earnings Snapshot

Neurocrine begins Phase III programme for schizophrenia treatment
NBIX

Clinical Trials Arena

9 days ago

Neurocrine begins Phase III programme for schizophrenia treatment

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential
NBIX

Insider Monkey

10 days ago

Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness’ Stock Picks with Huge Upside Potential

NBIX

MT Newswires

10 days ago

Neurocrine Biosciences Starting Phase 3 Trial of Prospective Schizophrenia Medication

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
NBIX

PR Newswire

10 days ago

Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NBIX

Zacks

11 days ago

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?
NBIX

Zacks

12 days ago

Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
NBIX

PR Newswire

16 days ago

Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry

Exploring 3 High Growth Tech Stocks In The US Market
NBIX

Simply Wall St.

17 days ago

Exploring 3 High Growth Tech Stocks In The US Market

NBIX

Argus Research

18 days ago

NBIX: Raising target price to $107.00

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case
NBIX

Simply Wall St.

18 days ago

With EPS Growth And More, Neurocrine Biosciences (NASDAQ:NBIX) Makes An Interesting Case

NBIX

Argus Research

25 days ago

NBIX: Raising target price to $101.00

NBIX

MT Newswires

25 days ago

Needham Upgrades Neurocrine Biosciences to Buy From Hold, $138 Price Target

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
NBIX

PR Newswire

a month ago

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

NBIX

MT Newswires

a month ago

Neurocrine Biosciences Faces Relatively Less Exposure to FDA and Tariff-Related Concerns, RBC Says

NBIX

MT Newswires

a month ago

RBC Upgrades Neurocrine Biosciences to Outperform From Sector Perform, Trims Price Target to $137 From $138

NBIX

Argus Research

a month ago

NBIX: Lowering target price to $92.00

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
NBIX

Zacks

a month ago

Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options

NBIX

MT Newswires

a month ago

Neurocrine Biosciences Appoints New Chief Medical Officer

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
NBIX

PR Newswire

a month ago

Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

NBIX

MT Newswires

a month ago

UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating

NBIX

MT Newswires

a month ago

Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating

NBIX

MT Newswires

a month ago

RBC Trims Price Target on Neurocrine Biosciences to $138 From $139, Keeps Sector Perform Rating

NBIX

Argus Research

a month ago

NBIX: Lowering target price to $112.00

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
NBIX

PR Newswire

a month ago

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

NBIX

Argus Research

a month ago

NBIX: Raising target price to $122.00

Exploring High Growth Tech Stocks in US for March 2025
NBIX

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks in US for March 2025

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza
NBIX

Clinical Trials Arena

2 months ago

Neurocrine Biosciences debuts new data for effectiveness of Ingrezza

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires
NBIX

Insider Monkey

2 months ago

Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
NBIX

The Wall Street Journal

2 months ago

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum

NBIX

MT Newswires

2 months ago

RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions
NBIX

Simply Wall St.

2 months ago

Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
NBIX

Clinical Trials Arena

2 months ago

Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

NBIX

Argus Research

2 months ago

NBIX: Lowering target price to $119.00

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
NBIX

PR Newswire

2 months ago

Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures

NBIX

Argus Research

2 months ago

NBIX: Raising target price to $122.00

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences to Present at Upcoming Investor Conferences in March

High Growth Tech Stocks To Watch In February 2025
NBIX

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In February 2025

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?
NBIX

Insider Monkey

3 months ago

Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now?

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest
NBIX

Simply Wall St.

3 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) Performance Is Even Better Than Its Earnings Suggest

NBIX

MT Newswires

3 months ago

Sector Update: Health Care Stocks Mixed Premarket Friday

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Approves $500 Million Share Repurchase Program

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program

NBIX

Argus Research

3 months ago

NBIX: Lowering target price to $120.00

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January
NBIX

Insider Monkey

3 months ago

Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $1,613,923, According to a Recent SEC Filing

NBIX

MT Newswires

3 months ago

Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Hold Rating, $138 Price Target

Why Neurocrine Biosciences Stock Sank Today
NBIX

Motley Fool

3 months ago

Why Neurocrine Biosciences Stock Sank Today

NBIX

MT Newswires

3 months ago

UBS Adjusts Neurocrine Biosciences Price Target to $154 From $176, Maintains Buy Rating

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week
NBIX

Insider Monkey

3 months ago

Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday
NBIX

Insider Monkey

3 months ago

Here’s Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years
NBIX

Simply Wall St.

3 months ago

Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
NBIX

Investor's Business Daily

3 months ago

Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More
NBIX

Barrons.com

3 months ago

These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
NBIX

Benzinga

3 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

NBIX

MT Newswires

3 months ago

RBC Capital Adjusts Price Target on Neurocrine Biosciences to $148 From $154, Keeps Sector Perform Rating

NBIX

MT Newswires

3 months ago

Wedbush Adjusts Price Target on Neurocrine Biosciences to $147 From $157, Keeps Outperform Rating

NBIX

MT Newswires

3 months ago

Sector Update: Health Care Stocks Lower Pre-Bell Friday

These Stocks Are Moving the Most Today: Amazon, Tesla, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More
NBIX

Barrons.com

3 months ago

These Stocks Are Moving the Most Today: Amazon, Tesla, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More

NBIX

MT Newswires

3 months ago

Sector Update: Health Care

NBIX

Thomson Reuters StreetEvents

3 months ago

Q4 2024 Neurocrine Biosciences Inc Earnings Call

NBIX

GuruFocus.com

3 months ago

Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ...

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
NBIX

Zacks

3 months ago

Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $160.00

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $413,967, According to a Recent SEC Filing

Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now
NBIX

Insider Monkey

3 months ago

Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
NBIX

Zacks

3 months ago

Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Insider Sold Shares Worth $21,836,503, According to a Recent SEC Filing

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
NBIX

Zacks

3 months ago

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

NBIX

Argus Research

3 months ago

NBIX: Raising target price to $158.00

NBIX

MT Newswires

3 months ago

Neurocrine Biosciences Begins Phase 3 Study of Osavampator in Major Depressive Disorder

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
NBIX

Benzinga

3 months ago

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

NBIX

MT Newswires

3 months ago

Neurocrine Amends Collaboration with Takeda on Osavampator

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
NBIX

PR Newswire

3 months ago

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
NBIX

PR Newswire

4 months ago

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

NBIX

MT Newswires

4 months ago

Wedbush Lifts Price Target on Neurocrine Biosciences to $157 From $154, Keeps Outperform Rating

NBIX

Argus Research

4 months ago

NBIX: Rating increased to a HOLD

Share on Social Networks: